Oxidative stress and endothelial function: Therapeutic interventions

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 2, 2011, Pages 103-114

  Tousoulis, Dimitris ^a   Briasoulis, Alexandros ^a   Papageorgiou, Nikolaos ^a   Tsioufis, Costas ^a   Tsiamis, Eleftherios ^a   Toutouzas, Kostas ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Endothelial dysfunction; Nitric oxide; Oxidative stress; Patents

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ACETYLCYSTEINE; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOCYNIN; ASCORBIC ACID; ATORVASTATIN; CAPTOPRIL; DIPHENYLIODONIUM SALT; ENALAPRILAT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; FOLIC ACID; GLITAZONE DERIVATIVE; GLUCOSE OXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOCORTIN 5; LIPOXYGENASE; LISINOPRIL; MEVINOLIN; NEBIVOLOL; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESVERATROL; TETRAHYDROBIOPTERIN; XANTHINE OXIDASE; ZOFENOPRILAT;

ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BIOAVAILABILITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; EXERCISE; FOREARM BLOOD FLOW; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; LOW DRUG DOSE; MITOCHONDRIAL ENERGY TRANSFER; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; SMOKING; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; OXIDATIVE STRESS; PATENTS AS TOPIC; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 79959348307     PISSN: 15748901     EISSN: 15748901     Source Type: Journal    
DOI: 10.2174/157489011795933819     Document Type: Article

References (117)

1. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007; 115: 1285-95.
2. Jung O, Marklund SL, Xia N, Busse R, Brandes RP. Inactivation of extracellular superoxide dismutase contributes to the development of high-volume hypertension. Arterioscler Thromb Vasc Biol 2007; 27: 470-7.
3. Yang H, Roberts LJ, Shi MJ, Zhou LC, Ballard BR, Richardson A, et al. Retardation of atherosclerosis by over- expression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E. Circ Res 2004; 95: 1075-81.
4. Yoshida T, Maulik N, Engelman RM, Ho YS, Magnenat JL, Rousou JA, et al. Glutathione peroxidase knockout mice are susceptible to myocardial ischemia reperfusion injury. Circulation 1997; 96: 216-20.
5. Torzewski M, Ochsenhirt V, Kleschyov AL, Oelze M, Daiber A, Li H, et al. Deficiency of glutathione peroxidase-1 accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 850-7.
6. Stocker R, Perrella MA. Heme oxygenase-1: A novel drug target for atherosclerotic diseases? Circulation 2006; 114: 2178-89.
7. Yamawaki H, Haendeler J, Berk BC. Thioredoxin: A key regulator of cardiovascular homeostasis. Circ Res 2003; 93: 1029-33.
8. Widlansky ME, Gokce N, Keaney JF Jr. Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-60.
9. Tousoulis D, Davies G, Crake T, Lerman A, Hasdai D, Holmes D. Acetylcholine and endothelial function. Circulation 1998; 98: 1587A-90A.
10. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002; 39: 257-65.
11. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000; 87: 840-4.
12. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1- receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002; 15: 590-3.
13. Irani K. Oxidant signaling in vascular cell growth, death and survival: A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000; 87: 179-83.
14. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996; 97: 1916-23.
15. Hegde LG, Srivastava P, Kumari R, Dikshit M. Alterations in the vasoreactivity of hypertensive rat aortic rings: Role of nitric oxide and superoxide radicals. Clin Exp Hypertens 1998; 20: 885-901.
16. Hornig B. Vitamins, antioxidants and endothelial function in coronary artery disease. Cardiovasc Drugs Ther 2002; 16: 401-9.
17. Andreozzi F, Laratta E, Sciacqua A, Perticone F, Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 2004; 94(9): 1211-8.
18. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, et al. Tetrahydrobiopterin improves endotheliumdependent vasodilation in chronic smokers: Evidence for a dysfunctional nitric oxide synthase. Circ Res 2000; 86: E36-E41.
19. Stoes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41-6.
20. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemia-reperfusion selectively impairs nitric oxide mediated dilation in coronary arterioles: Counteracting role of arginase. FASEB J 2003; 17: 2328-30.
21. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003; 108: 2000-6.
22. Sydow K, Schwedhelm E, Arakawa N, Bode-Boger SM, Tsikas D, Hornig B, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of Larginine and B vitamins. Cardiovasc Res 2003; 57: 244-52.
23. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-92.
24. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene Study. Circ Res 2005; 97: e53-e59.
25. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis [Theodore Cooper Lecture]. Hypertension 2001; 37: 1047-52.
26. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Etayo JC, et al. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000; 35: 1055-61.
27. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance? Hypertension 2004; 44: 248-52.
28. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, et al. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: E85-E90.
29. Yamashita N, Hoshida S, Otsu K, Asahi M, Kuzuya T, Hori M. Exercise provides direct biphasic cardioprotection via manganese superoxide dismutase activation. J Exp Med 1999; 189: 1699-706.
30. Rush JW, Turk JR, Laughlin MH. Exercise training regulates SOD-1 and oxidative stress in porcine aortic endothelium. Am J Physiol Heart Circ Physiol 2003; 284: H1378-H187.
31. Stralin P, Karlsson K, Johansson BO, Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 1995; 11: 2032-6.
32. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 2000; 105: 1631-9.
33. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase. Circulation 2001; 103: 799-805.
34. Jialal I, Norkus EP, Cristol L, Grundy SM. beta-Carotene inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1991; 1086: 134-8.
35. Keaney JF Jr., Gaziano JM, Xu A, Frei B, Curran-Celentano J, Shwaery GT, et al. Dietary antioxidants preserve endotheliumdependent vessel relaxation in cholesterol-fed rabbits. Proc Natl Acad Sci USA 1993; 90: 11880-4.
36. Keaney JF Jr., Gaziano JM, Xu A, Frei B, Curran-Celentano J, Shwaery GT, et al. Low-dose alpha-tocopherol improves and highdose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994; 93: 844-51.
37. Andersson TL, Matz J, Ferns GA, Anggård EE. Vitamin E reverses cholesterol-induced endothelial dysfunction in the rabbit coronary circulation. Atherosclerosis 1994; 111: 39-45.
38. Toutouzas P, Tousoulis D, Davies GJ. Nitric oxide synthesis in atherosclerosis. Eur Heart J 1998; 19: 1504-11.
39. Tousoulis D, Antoniades C, Tentolouris C, Tsioufis C, Toutouza M, Toutouzas P, et al. Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. Atherosclerosis 2003; 170: 261-7.
40. Antoniades C, Tousoulis D, Tentolouris C, Toutouza M, Marinou K, Goumas G, et al. Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost 2003; 89: 990-5.
41. Tousoulis D, Davies F, Toutouzas P. Effects of vitamin C on nitric oxide activity in coronary atherosclerosis. Ann Intern Med 1999; 131: 156-7.
42. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium- dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222-9.
43. Tousoulis D, Antoniades C, Tountas C, Bosinakou E, Kotsopoulou M, Toutouzas P, et al. Vitamin C affects thrombosis/fibrinolysis system and reactive hyperemia in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2003; 26: 2749-53.
44. Tousoulis D, Antoniades C, Vasiliadou C, Kourtellaris P, Koniari K, Marinou K, et al. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart. 2007; 93: 244-6.
45. Kinlay S, Fang JC, Hikita H, Ho I, Delagrange DM, Frei B, et al. Plasma α-tocopherol and coronary endothelium-dependent vasodilator function. Circulation 1999; 100: 219-21.
46. Cangemi R, Loffredo L, Carnevale R, Perri L, Patrizi MP, Sanguigni V, et al. Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: Effect on circulating vitamin E. Eur Heart J. 2008; 29: 54-62.
47. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res. 2002; 91: 173-9.
48. Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, et al. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2010; 30(2): 360-7.
49. Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMGCoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-9.
50. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction-modulation by statins. Endothelium 2003; 10: 23-33.
51. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009; 119: 131-138.
52. Girona J, La Ville AE, Solà R, Plana N, Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999; 83: 846-51.
53. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interaction of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998; 31: 39-45.
54. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96.
55. Inoue T, Inoue K, Maeda H, Takayanagi K, Morooka S. Immunological response to oxidized LDL occurs in association with oxidative DNA damage independently of serum LDL concentrations in dyslipidemic patients. Clin Chim Acta 2001; 305: 115-21.
56. Inoue T, Takayanagi K, Hayashi T, Morooka S. Fluvastatin attenuate nitrate tolerance in patients with ischemic heart disease. Int J Cardiol 2003; 90: 181-8.
57. Benedini, F., Ongini, E., Del Soldato, P. Statin derivatives. US7563909 (2008).
58. Fogelman, A., Anantharamaiah, G.M., Navab, M. Orally administered peptides synergize statin activity. US7820784 (2008).
59. Fogelman, A., Anantharamaiah, G.M., Navab, M. Orally administered peptides to ameliorate atherosclerosis. US6933279 (2005).
60. Stroes, E. Treatment of endothelial dysfunction in diabetic patients. EP1964571 (2007).
61. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589-96.
62. Cominacini L, Fratta Pasini A, Garbin U, Nava C, Davoli A, Criscuoli M, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003; 42: 1838-84.
63. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005; 112: 3795-801.
64. Evangelista S, Garbin U, Pasini AF, Stranieri C, Boccioletti V, Cominacini L. Effect of dl-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res 2007; 55: 303-9.
65. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, et al. Nebivolol prevents NADPH oxidase mediated superoxide formation and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006; 48: 677-84.
66. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part I: Oxidative stress and atherogenesis. Circulation 2002; 105: 393-6.
67. Pasini AF, Garbin U, Nava MC, Stranieri C, Pellegrini M, Boccioletti V, et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20: 443-50.
68. Cominacini L, Pasini A, Garbin U, Evangelista S, Crea AE, Tagliacozzi D, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15: 891-5.
69. Liu X, Engelman RM, Rousou JA, Cordis GA, Das DK. Attenuation of myocardial reperfusion injury by sulfhydrylcontaining angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther 1992; 6: 437-43.
70. Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990; 40: 2169-75.
71. Desideri G, Grassi D, Croce G, Bocale R, Tiberti S, Evangelista S, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: Evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008; 2008: 305087.
72. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: Implications for cardiovascular disease. Hypertension 2004; 43: 297-305.
73. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor g ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-57.
74. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2005; 288: C899-905.
75. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339: 1523-6.
76. Hertog MG, Feskens EJ, Kromhout D. Antioxidant flavonols and coronary heart disease risk. Lancet 1997; 349: 699.
77. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, et al. Flavonoid intake and cardiovascular disease mortality: A prospective study in postmenopausal women. Am J Clin Nutr 2007; 85: 895-909.
78. Buijsse B, Feskens EJ, Kok FJ, Kromhout D. Cocoa intake, blood pressure, and cardiovascular mortality: The Zutphen Elderly Study. Arch Intern Med 2006; 166: 411-7.
79. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: Food sources and bioavailability. Am J Clin Nutr 2004; 79: 727-47.
80. Fuhrman B, Aviram M. Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr Opin Lipidol 2001; 12: 41-8.
81. Nigdikar SV, Williams NR, Griffin BA, Howard AN. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. Am J Clin Nutr 1998; 68: 258-65.
82. Gorelik S, Lapidot T, Shaham I, Granit R, Ligumsky M, Kohen R, et al. Lipid peroxidation and coupled vitamin oxidation in simulated and human gastric fluid inhibited by dietary polyphenols: Health implications. J Agric Food Chem 2005; 53: 3397-402.
83. Flammer AJ, Hermann F, Sudano I, Spieker L, Hermann M, Cooper KA, et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 2007; 116: 2376-82.
84. Bertelli AA. Wine, research and cardiovascular disease: Instructions for use, Atherosclerosis 2007; 195: 242-7.
85. Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2006; 16: 296-300.
86. Csiszar A, Labinskyy N, Podlutsky A, Kaminski PM, Wolin MS, Zhang C, et al. Vasoprotective effects of resveratrol and SIRT1: Attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol 2008; 294: H2721-35.
87. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: From folate fortification to the recent clinical trials. Eur Heart J 2009; 30: 6-15.
88. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006; 114: 1193-201.
89. Shirodaria C, Antoniades C, Lee J, Jackson CE, Robson MD, Francis JM, et al. Global improvement of vascular function and redox state with low-dose folic acid: Implications for folate therapy in patients with coronary artery disease. Circulation 2007; 115(17): 2262-70.
90. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.
91. Rabelink, T., Moser, R. Pharmaceutical preparation containing at least folic acid or a folate and tetrahydrobiopterin (BH4) or derivatives thereof used for the treating or preventing cardiovascular or neurological disorders by modulation of the activity of nitric oxide synthase (NOS). US6995158 (2006).
92. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.
93. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA 2008; 299(17): 2027-36.
94. Santoro, M.G., Rossi, A., Elia, G., Garaci, E., Amici, C. Methods of treating inflammatory and viral disorders by administering cyclopentenone compounds. US020687 (2005).
95. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
96. Gutierrez LL, Maslinkiewicz A, Curi R, de Bittencourt PI Jr. Atherosclerosis: A redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins. Biochem Pharmacol 2008; 75: 2245-62.
97. Le Naour, M., Pirat, C., Lebeque, N., Leclerc, V., Berthelot, B., Dacquet, C., Ktorza, A., Caignard, D.H. New heterocyclic compounds are aldose reductase inhibitors useful to treat e.g. hyperglycemia, dyslipidemia, non-insulin-dependent type II diabetes, syndrome X, coronary artery diseases, glomerulonephritis and psoriasis. FR2921366 (2009).
98. Bittencourt PI Jr., Lagranha DJ, Maslinkiewicz A, Senna SM, Tavares AM, Baldissera LP, et al. LipoCardium: Endotheliumdirected cyclopentenone prostaglandin based liposome formulation that completely reverses atherosclerotic lesions. Atherosclerosis 2007; 193: 245-58.
99. Spycher SE, Tabataba-Vakili S, O'Donnell VB, Palomba L, Azzi A. Aldose reductase induction: A novel response to oxidative stress of smooth muscle cells. FASEB J 1997; 11: 181-8.
100. Lo AC, Cheung AK, Hung VK, Yeung CM, He QY, Chiu JF, et al. Deletion of aldose reductase leads to protection against cerebral ischemic injury. J Cereb Blood Flow Metab 2007; 27: 1496-509.
101. Murphy, M.P., Smith, R. Mitoquinone derivatives used as mitochondrially targeted antioxidants. US238709 (2007).
102. Gleissner CA, Sanders JM, Nadler J, Ley K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 1137-43.
103. Holland, J., Johnson, D. Use of NADPH oxidase inhibitors for a manufacture of medicament for prevention of atherosclerosis. GR3033067 (2000).
104. Frostegard, J., Pettersson, K. Compounds and methods for the treatment of vascular disease. WO077764 (2009).
105. Frostegard, A., Frostegard, J. Annexin V for preventing atherombosis and plaque rupture. WO099744 (2005).
106. Sukhatme, V. Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders. US199426 (2008).
107. Antoniades, C., Shirodaria, C., Channon, K.M., Moser, R. Use of folates for the prevention and treatment of vascular diseases. US2010064702 (2010).
108. Meng, C., Sikorksi, J. Phenolic antioxidants for the treatment of disorders including arthritis, asthma, and coronary artery disease. WO2005112914 (2005).
109. Berk, B.C. Thioredoxin interacting protein (TXNIP) as regulator of vascular function. WO2006078853 (2006).
110. Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, et al. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem 2004; 279: 37575-87.
111. Barua AB, Kostic D, Olsen J. New simplified procedures for the extraction and simultaneous high-performance liquid chromatographic analysis of retinol, tocopherols, and carotenoids in human serum. J Chromatogr 1993; 617: 257-64.
112. Wood LG, Gibson PG, Garg ML. A review of the methodology for assessing in vivo antioxidant capacity. J Sci Food Agric 2006; 86: 2057-66.
113. Awad JA, Roberts LJ 2nd, Burk RF, Morrow JD. Isoprostanes-prostaglandin-like compounds formed in vivo independently of cyclooxygenase: Use as clinical indicators of oxidant damage. Gastroenterol Clin N Am 1996; 25: 409-27.
114. Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of Middle-aged individuals with both type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype. Arterioscler Thromb Vasc Biol 2008; 28: 341-7.
115. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: Discovery and therapeutic potential. Nat Rev Drug Discov 2006; 5: 755-68.
116. Lockwood, S.F. Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status. WO067957 (2007).
117. Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: A Novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol 2008; 101: 58D-68D.